Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0A5TD
|
|||
Former ID |
DNC011300
|
|||
Drug Name |
NSC-621351
|
|||
Synonyms |
NSC-621351; CHEMBL1288223; NSC621351; AC1L7FC6; AC1Q4O4K; BDBM50332183; NCI60_006226; 2-(2-fluorophenyl)-4-naphthalen-2-yl-2,3-dihydro-1,5-benzothiazepine; 2-(2-fluorophenyl)-4-(naphthalen-2-yl)-2,3-dihydro-1,5-benzothiazepine
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
![]() |
Download2D MOL |
||
Formula |
C25H18FNS
|
|||
Canonical SMILES |
C1C(SC2=CC=CC=C2N=C1C3=CC4=CC=CC=C4C=C3)C5=CC=CC=C5F
|
|||
InChI |
1S/C25H18FNS/c26-21-10-4-3-9-20(21)25-16-23(27-22-11-5-6-12-24(22)28-25)19-14-13-17-7-1-2-8-18(17)15-19/h1-15,25H,16H2
|
|||
InChIKey |
WXTPJZLDXSZFPY-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Quinone reductase 1 (NQO1) | Target Info | Inhibitor | [1] |
KEGG Pathway | Ubiquinone and other terpenoid-quinone biosynthesis | |||
NetPath Pathway | TCR Signaling Pathway | |||
Pathwhiz Pathway | Vitamin K Metabolism | |||
Pathway Interaction Database | Validated transcriptional targets of TAp63 isoforms | |||
WikiPathways | Estrogen metabolism | |||
Oxidative Stress | ||||
Transcriptional activation by NRF2 | ||||
NRF2 pathway | ||||
Nuclear Receptors Meta-Pathway | ||||
Aryl Hydrocarbon Receptor Pathway | ||||
Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
Metabolism of amino acids and derivatives | ||||
Aryl Hydrocarbon Receptor | ||||
Dopamine metabolism | ||||
Arylhydrocarbon receptor (AhR) signaling pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.